A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

Inclusion Criteria: * Individuals aged 18 years and older who voluntarily decide to participate in this study and provide written informed consent * Female of childbearing potential who agree to use medically allowed methods of contraception during the study period * Individuals who agrees not to perform blood donation and transfusion during the study period Exclusion Criteria: * Individual being considered to be confirmed COVID-19 * Direct contact with COVID-19 infected person within 14 days prior to the 1st dose of the IP * Individuals at high risk of exposure to SARS-CoV-2 * Individuals with clinically significant abnormalities in clinical laboratory tests, ECGs, and chest X-ray during screening * Individuals with fever within 72 hours prior to the 1st dose of the IP or suspected other infectious disease or symptoms associated with other infectious disease * Individuals with serious medical or psychiatric disease * History of SARS-CoV or MERS-CoV infection * History of allergic reaction or hypersensitivity reactions to any of components of the IP * History of serious adverse events, serious allergic reaction or serious hypersensitivity reactions to vaccination * History of receiving organ or bone marrow transplant * Suspected or history of drug abuse or alcohol abuse within 6 months prior to vaccination * History of vaccination against SARS-CoV, MERS-CoV, or SARS-CoV-2 * History of vaccination with test vaccine substance * Treatment with immunosuppressants or immune modifying drugs * History of treatment with antipsychotics or opioid dependence * Pregnant or lactating women * Other reasons based on which the individual is considered to be ineligible for this study in the opinion of the investigator